Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
Key clinical point: Adding the AKT inhibitor ipatasertib to paclitaxel may provide an overall survival benefit for inoperable locally advanced/metastatic triple-negative breast cancer (TNBC).
Major finding: The median overall survival was 25.8 months with ipatasertib plus paclitaxel and 16.9 months with paclitaxel plus placebo (hazard ratio, 0.80; 95% confidence interval, 0.50-1.28).
Study details: The phase 2 LOTUS trial of 124 patients with advanced/metastatic TNBC.
Disclosures: The LOTUS trial was funded by Roche/Genentech. Dr. Dent reported receiving honoraria from Roche, Novartis, Lilly, Pfizer, Eisai, Merck, and AstraZeneca.
Dent R et al. ESMO Breast Cancer Conference 2020, Abstract 139O.